Cullinan Oncology, Inc. announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.81 USD | +1.63% | -3.50% | +162.51% |
May. 09 | Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing | MT |
Apr. 29 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+162.51% | 1.14B | |
+29.66% | 49.18B | |
+0.94% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.58% | 26.09B | |
-22.77% | 18.71B | |
+8.35% | 13.26B | |
+32.12% | 12.32B | |
-0.89% | 11.99B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines